跳至主要内容
临床试验/NCT04935463
NCT04935463已完成不适用

Mucormycosis in COVID-19

Montefiore Medical Center1 个研究点 分布在 1 个国家目标入组 728 人开始时间: 2021年5月24日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
728
试验地点
1
主要终点
Vision loss

研究概览

简要总结

The purpose is to allow phsyician reporters to contribute to MUNCO registry. Mucormycosis in COVID-19 is a rapidly escalating medical emergency reported in high numbers in India during the ongoing coronavirus surge. There is very little known about the risk factors, patterns and complications of mucormycosis as it occurs either during the infection or treatment phase of the novel coronavirus (COVID-19). In light of this emerging epidemic within a pandemic, it is of time sensitive importance to obtain a better understanding of the risk factors and outcomes of this fatal complication

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Diagnosed case of Mycotic Infection in COVID-19

排除标准

  • 未提供

结局指标

主要结局

Vision loss

时间窗: 60 days

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shitij Arora

Associate Professor

Montefiore Medical Center

研究点 (1)

Loading locations...

相似试验